Ministry of Health and Family WelfareHealthIndiaCOVID-19

COVID – 19 Vaccination Update – Day 418

India’s cumulative vaccination coverage crosses 179.51 Crore. More than 15 lakh Vaccine doses administered today till 7 pm

India’s COVID-19 vaccination coverage has crossed 179.51 Crore (1,79,51,20,996) today. More than 15 lakh (15,95,870Vaccine Doses have been administered till 7 pm today. More than 2.09 Crore (2,09,37,264) Precaution Doses for the identified categories of beneficiaries (HCWs, FLWs and Over 60 years) for COVID vaccination have been administered so far. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

The cumulative coverage of vaccine doses, segregated based on population priority groups, is as follows:

Cumulative Vaccine Dose Coverage
HCWs 1st Dose 10402357
2nd Dose 9980095
Precaution Dose 4278528
FLWs 1st Dose 18410932
2nd Dose 17468609
Precaution Dose 6455429
Age Group 15-18 years 1st Dose 55646222
  2nd Dose 32443946
Age Group 18-44 years 1st Dose 552957961
2nd Dose 452436697
Age Group 45-59 years 1st Dose 202464810
2nd Dose 182045794
Over 60 years 1st Dose 126550892
2nd Dose 113375417
Precaution Dose 10203307
Cumulative 1st dose administered 966433174
Cumulative 2nd dose administered 807750558
Precaution Dose 20937264
Total 1795120996

 

Today’s achievement in the vaccination exercise, segregated by population priority groups, is as follows:

Date: 9th March, 2022 (418th Day)
HCWs 1st Dose 52
2nd Dose 1086
Precaution Dose 8975
FLWs 1st Dose 85
2nd Dose 1972
Precaution Dose 13304
Age Group 15-18 years 1st Dose 60875
  2nd Dose 379862
Age Group 18-44 years 1st Dose 87430
2nd Dose 699396
Age Group 45-59 years 1st Dose 12863
2nd Dose 161526
Over 60 years 1st Dose 9169
2nd Dose 104409
Precaution Dose 54866
Cumulative 1st dose administered 170474
Cumulative 2nd dose administered 1348251
Precaution Dose 77145
Total 1595870

 

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment moderation is enabled. Your comment may take some time to appear.

Back to top button

Adblock detected

Please consider supporting us by disabling your ad blocker